Nelly Yu. Andreeva

article 2023

Evaluation of survivin expression in the endometrium and endometriotic lesions in patients with genital endometriosis, type 1 diabetes mellitus and their comorbidity

·doi:10.17816/jowd345406

BACKGROUND: The prevalence of external genital endometriosis is high, yet there is insufficient understanding of its etiology and pathogenesis. This coupled with the challenges posed by its diagnosis and treatment, and its co-occurrence wit…

article 2023

The potential of survivin as a non-invasive diagnostic marker for endometriosis in patients with type 1 diabetes mellitus

·doi:10.17816/jowd567975

BACKGROUND: According to international data, about 5-10% of women of reproductive age suffer from this disease, while in women with chronic pelvic pain or infertility the incidence ranges from 35% to 50%. At the same time, women of reproduc…

article 2022

Analysis of polymorphic variants of the survivin promoter and p53 transcription factor in patients with genital endometriosis, type 1 diabetes mellitus and their combination

·doi:10.17816/jowd89528

AIM: The aim of this study was to analyze the association between the SNP surviving, the p53 gene polymorphisms and the risk of developing genital endometriosis and type 1 diabetes mellitus. MATERIALS AND METHODS: The frequency of allelic …

article 2020

The oral gonadotropin-releasing hormone antagonists: contemporary possibilities and perspectives of application

·doi:10.17116/repro20202605178

В настоящее время антагонисты гонадотропин-рилизинг-гормона широко используются для предотвращения преждевременного выброса лютеинизирующего гормона во время контролируемой стимуляции суперовуляции в программах вспомогательных репродуктивн…